TRDA

Entrada Therapeutics Stock Analysis

AI Rating

Low
  • Quality4/10
  • Growth↓ 2/10
  • Value↓ 0/10
Entrada Therapeutics sales and earnings growth
TRDA Growth
Fair
  • Revenue Y/Y↓ -87.94%
  • EPS Y/Y↓ -297.16%
  • FCF Y/Y↓ -189.73%
Entrada Therapeutics gross and profit margin trends
TRDA Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -565.50%
  • ROIC 5Y↓ -5.49%
Entrada Therapeutics net debt vs free cash flow
TRDA Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Entrada Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗